- Home
- PBT vs PHAR Comparison
PBT vs PHAR Comparison
Compare PBT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | PHAR |
|---|---|---|
| Founded | 1980 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBT | PHAR |
|---|---|---|
| Price | $17.07 | $16.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 81.7K | 23.0K |
| Earning Date | 03-13-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | 0.00 |
| Revenue | $17,266,423.00 | ★ $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | N/A | $6.84 |
| P/E Ratio | ★ $50.39 | $2,916.44 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $8.01 | $7.50 |
| 52 Week High | $20.46 | $18.12 |
Technical Indicators
Market Signals| Indicator | PBT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 51.04 |
| Support Level | $16.25 | $16.23 |
| Resistance Level | $18.73 | $18.12 |
| Average True Range (ATR) | 0.72 | 0.83 |
| MACD | -0.16 | -0.13 |
| Stochastic Oscillator | 25.32 | 36.86 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.